Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

3(60.0%)

Phase 4

1(20.0%)

Phase 2

1(20.0%)

5Total

Phase 1(3)

Phase 4(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT03848806Phase 2Completed

Efficacy and Safety of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis

Role: lead

NCT03089229Phase 1Completed

A Study to Evaluate the Efficacy and Safety of HAT01H in Atopic Dermatitis

Role: lead

NCT03406117Phase 4Completed

A Study to Determine the Safety and Sensitizing Potential of HAT1 Topical Products Using Skin Sensitivity Patch Tests

Role: lead

NCT03069144Phase 1Completed

Efficacy and Tolerability of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis

Role: lead

NCT03059693Phase 1Completed

Efficacy and Tolerability of HAT1 in Patients With Moderate to Severe Atopic Dermatitis

Role: lead

All 5 trials loaded